Long acting ß2-agonists and glucocorticoids together control asthma in ~95% of affected individuals, although symptoms return after treatment is stopped. Treatment of chronic obstructive pulmonary disease (COPD) scarcely influences the natural course of the disease. Neither long-acting ß2-agonists (LABAs) nor glucocorticoids alone significantly influence the course of COPD. Recent evidence suggests that a combination of the two therapies is more promising. It can decrease the exacerbation rates in severe COPD and may also decrease mortality.
Interactions between long-acting ß2-agonists and glucocorticoids
CARAMORI, Gaetano;PAPI, Alberto;
2006
Abstract
Long acting ß2-agonists and glucocorticoids together control asthma in ~95% of affected individuals, although symptoms return after treatment is stopped. Treatment of chronic obstructive pulmonary disease (COPD) scarcely influences the natural course of the disease. Neither long-acting ß2-agonists (LABAs) nor glucocorticoids alone significantly influence the course of COPD. Recent evidence suggests that a combination of the two therapies is more promising. It can decrease the exacerbation rates in severe COPD and may also decrease mortality.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.